Track NervGen Pharma Corp. Common stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NervGen Pharma Corp. Common stock NGEN Open NervGen Pharma Corp. Common stock in new tab

3.64 USD
EPS
-0.45
P/B
110.85
ROE
-1207.46
Beta
0.99
Target Price
10.39 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 12, 2026
EPS-0.45
Book Value0.03
Price to Book110.85
Debt/Equity0.24
% Insiders20.744%
Estimates
Forward P/E-9.39
Forward EPS-0.38
Target Mean Price10.39

DCF Valuation

Tweak assumptions to recompute fair value for NervGen Pharma Corp. Common stock (NGEN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NervGen Pharma Corp. Common stock Logo NervGen Pharma Corp. Common stock Analysis (NGEN)

Canada Healthcare Official Website Stock

Is NervGen Pharma Corp. Common stock a good investment? NervGen Pharma Corp. Common stock (NGEN) is currently trading at 3.64 USD. Market analysts have a consensus price target of 10.39 USD. This suggests a potential upside from current levels.

Earnings Schedule: NervGen Pharma Corp. Common stock is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -0.38.

Investor FAQ

Does NervGen Pharma Corp. Common stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is NervGen Pharma Corp. Common stock?

NervGen Pharma Corp. Common stock is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -0.45.

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Exchange Ticker
NASDAQ NGEN
VAN (Canada) NGEN.V
PNK (United States) NGENF

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion